Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fuso Pharmaceutical Industries,Ltd. (4538.T)
Osaka, JP
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.65% | -8.99% | -11.92% | -13.87% | -6.64% | -12.30% | -12.45% | -1.22% | -8.87% | -28.95% | -57.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.9% Q1'26: +1.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+161.2% ★ Q1'26: +105.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-10.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.2% Q1'26: +1.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.7% Q1'26: +1.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.41× Q1'26: 7.69× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.04% | 150.3K | 0.58% |
| 2 | WisdomTree International Equity Fund DWM | 0.01% | 65.4K | 0.48% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 189.2K | 0.42% |
| 4 | Dimensional - International Small Cap ETF DFIS | 0.00% | 162.3K | 0.39% |
| 5 | iShares Core TOPIX ETF 1475.T | 0.00% | 255.5K | 0.05% |
| 6 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 83.9K | 0.22% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 58.7K | 0.28% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 1.3K | 0.30% |
| 9 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haruhiko Furuichi | Senior Exec Officer, GM of Gen. Affairs Div., Head of the General Affairs Dept and Accounting Dept | — | — |
| Hideki Otani | GM of Sales Division & Director | — | male |
| Hirohumi Yamamoto | Executive Officer & Factory Manager of Ibaraki Factory and Production Division | — | — |
| Jun-Ichi Oka | GM of Production Division & Director | — | male |
| Masanori Ito | Manager of R&D Center & Director | — | male |
| Michikazu Saito | Executive Officer of Osaka Branch Sales Division | — | — |
| Mikihiro Toda | Executive Managing Officer of Corporate Planning Div. & Representative Director | — | male |
| Mikio Toda | President & Representative Director | — | male |
| Mitsuro Uotani | Executive Officer & Head of Distribution Management Dept. and Sales Division | — | — |
| Satoshi Tanaka | Executive Officer & GM of Reliability Assurance Division | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4538.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
